https://www.gabionline.net/biosimilars/research/switching-from-adalimumab-originator-and-abp501-to-sb5-in-arthritis-patients
Switching from adalimumab originator and ABP501 to SB5 in arthritis patients
The introduction and availability of biosimilars entails a considerable increase in the patient access as well as a decrease in the patient cost. T...
switchingadalimumaboriginator